NEW YORK, NY / ACCESSWIRE / April 26, 2016 / The OTC Expert is issuing a report on four stocks that are trading with heavier than usual volume. LPTN, TLOG, HTM and VSTM are on high volume watch. Continue reading to find out why these stocks are getting so much interest today. - If you want reports on the day's hottest stocks (NYSE/Nasdaq/OTC) subscribe to our newsletter at otc-expert.com.

Verastem, Inc. (NASDAQ: VSTM) Is a biopharmaceutical company that focuses on discovering and developing drugs targeting cancer stem cells (CSCs). Its programs target the focal adhesion kinase (FAK) and the PI3K/mTOR signaling pathways.

When we first alerted our members on VSTM, back in early March, it was trading at just $1.14. Today, it is trading at $1.86 for a gain of 63% in just 2 months.

Shares of VSTM traded higher yesterday by 17% and the stock has been trading higher in the last three trading days, however, yesterday it received an influx in volume and the stock responded well to it.

We will continue to follow VSTM as it continues to make stay above its 200 day moving average.

Subscribe Free To Receive Alerts Like These Sent To Your Inbox Get Your Free Membership Now.

TetraLogic Pharmaceuticals Corporation (NASDAQ: TLOG) Is a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics in oncology and infectious diseases.

TLOG has been moving higher since early April, with several big days intermingled with some low volume days, however, yesterday was a different story.

TLOG ran up 66% off 16 times its average volume yesterday. We are hoping to see that this kind of run continues in this new biotech as the stock is up over 100% in April.

Like What You See? Get These Alerts and Many More on NASDAQ Companies before They Rally, Find Out More Here.

U.S. Geothermal Inc. (NYSE: HTM) Is a renewable energy company, focuses on the development, production, and sale of electricity from geothermal energy in the Western United States.

We started following HTM back in early March. Since then, the stock has made steady, but impressive gains of about 1 to 4 percent on most days.

Yesterday Aegis Capital initiated coverage on HTM and the stock got an influx of volume. The stock only made gains of 4% off the coverage announcement, however, this is a good sign that this slow and steady stock is going to continue making gains in the near future.

Get the Information You Need To Stay Informed and Up To Date On The Hottest NASDAQ Plays Get Them Here.

Lpath Inc. (NASDAQ: LPTN) Is a biotechnology company that focuses on the discovery and development of lipidomic-based therapeutic antibodies to treat a range of human diseases in the United States.

Shares of LPTN traded higher yesterday by over 24%. The stock appears to be continuing its trend higher in early 2016. However, since April, the stock has really been taking off, seeing an increase in volume and price increase, especially after breaking out past its 50 and 200 day MA (moving averages).

On April 19th the company announced the completion of its Phase 1 double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, immunogenicity and pharmacokinetics of Lpathomab? in healthy volunteers.

NASDAQ Stock Alerts: Check Them Out Here To Receive Our Winning NASDAQ & NYSE Stock Alerts For Free.

About otc-expert.com

The OTC Expert is a newsletter alert service that focuses on companies on the NASDAQ & NYSE. We only highlight quality companies with big news on high volume days. This commitment provides our subscribers with only the best recommendations of companies for short and long-term investments.

To receive free text message alerts on your phone, compose a new text message to the number 95577 with the word "OTCLEADER".

Disclosure: The information, opinions and analysis contained in this report are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor's or other person's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security. Past gains are not representative of future gains. The OTC Expert has not been compensated nor does it expect to receive any compensation for distribution of its opinions and publicly available information regarding the companies reported in this investment opinion article at this time. The opinions contained herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words "anticipate," "intend," "estimate," "believe," "expect," "plans," "should," "potential," "forecast," and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company's actual results could differ materially from those described in any forward-looking statements contained herein. The OTC Expert is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk. Please visit otc-expert.com/disclaimer website for a more detailed discussion of risks and disclosures.

Contact:

Justin Skibinski
The OTC Expert
info@otc-expert.com

SOURCE: The OTC Expert